Prognostic Biomarkers in Early-stage Gastric Adenocarcinoma Treated With Adjuvant Chemoradiotherapy.

Adenocarcinoma / genetics Biomarkers, Tumor / genetics Chemoradiotherapy, Adjuvant Female Follow-Up Studies Humans Male Middle Aged Mutation Neoplasm Staging PTEN Phosphohydrolase / genetics Prognosis Proto-Oncogene Proteins p21(ras) / genetics Retrospective Studies Stomach Neoplasms / genetics Survival Rate
Biomarkers chemoradiotherapy gastric cancer

Journal

Cancer genomics & proteomics
ISSN: 1790-6245
Titre abrégé: Cancer Genomics Proteomics
Pays: Greece
ID NLM: 101188791

Informations de publication

Date de publication:
Historique:
received: 22 01 2020
revised: 21 02 2020
accepted: 29 02 2020
entrez: 30 4 2020
pubmed: 30 4 2020
medline: 24 11 2020
Statut: ppublish

Résumé

Early-stage gastric cancer has a high risk of recurrence, despite trimodality therapy with surgery, chemotherapy and radiation. To improve patient selection for adjuvant chemoradiotherapy, we evaluated the prognostic significance of immunohistochemical and genetic biomarkers in patients with resected gastric adenocarcinoma. Tumors from 119 patients were subjected to immunohistochemistry for 12 protein biomarkers, as well as next-generation sequencing. Clinical and biomarker data were available for 91 patients. EBV-positive tumors and tumors with mutations had higher intratumoral CD8 tumor-infiltrating lymphocyte density (p=0.009 and p=0.017, respectively). PIK3CA mutations were correlated with VEGFA overexpression (p=0.042), while KRAS mutations and HER2 expression were mutually exclusive (p=0.036). PTEN expression univariately confirmed longer overall survival (HR=0.27; p=0.046), while there was a trend between the presence of KRAS mutations and inferior disease-free and overall survival. PTEN protein expression and KRAS mutations may predict disease outcome in early-stage gastric cancer. These results need to be further validated in larger cohorts.

Sections du résumé

BACKGROUND/AIM OBJECTIVE
Early-stage gastric cancer has a high risk of recurrence, despite trimodality therapy with surgery, chemotherapy and radiation. To improve patient selection for adjuvant chemoradiotherapy, we evaluated the prognostic significance of immunohistochemical and genetic biomarkers in patients with resected gastric adenocarcinoma.
PATIENTS AND METHODS METHODS
Tumors from 119 patients were subjected to immunohistochemistry for 12 protein biomarkers, as well as next-generation sequencing. Clinical and biomarker data were available for 91 patients.
RESULTS RESULTS
EBV-positive tumors and tumors with mutations had higher intratumoral CD8 tumor-infiltrating lymphocyte density (p=0.009 and p=0.017, respectively). PIK3CA mutations were correlated with VEGFA overexpression (p=0.042), while KRAS mutations and HER2 expression were mutually exclusive (p=0.036). PTEN expression univariately confirmed longer overall survival (HR=0.27; p=0.046), while there was a trend between the presence of KRAS mutations and inferior disease-free and overall survival.
CONCLUSION CONCLUSIONS
PTEN protein expression and KRAS mutations may predict disease outcome in early-stage gastric cancer. These results need to be further validated in larger cohorts.

Identifiants

DOI: 10.21873/cgp.20188 PMID: 32345669 PMC: PMC7259883
pubmed: 32345669
pii: 17/3/277
doi: 10.21873/cgp.20188
pmc: PMC7259883
doi:

Substances chimiques

Biomarkers, Tumor 0
KRAS protein, human 0
PTEN Phosphohydrolase EC 3.1.3.67
PTEN protein, human EC 3.1.3.67
Proto-Oncogene Proteins p21(ras) EC 3.6.5.2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

277-290

Informations de copyright

Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Références

Anticancer Res. 2011 Oct;31(10):3543-54
pubmed: 21965776
Clin Cancer Res. 2005 Nov 15;11(22):8208-12
pubmed: 16299254
PLoS One. 2016 Dec 22;11(12):e0168085
pubmed: 28005970
Sci Rep. 2016 Mar 10;6:22982
pubmed: 26961069
Cancer Discov. 2018 Jan;8(1):37-48
pubmed: 28978556
Nat Med. 2018 Sep;24(9):1449-1458
pubmed: 30013197
ESMO Open. 2018 Mar 15;3(3):e000326
pubmed: 29636988
Methods Mol Biol. 2013;999:223-30
pubmed: 23666702
J Clin Oncol. 2004 May 15;22(10):1878-85
pubmed: 15143080
N Engl J Med. 2006 Jul 6;355(1):11-20
pubmed: 16822992
BMC Cancer. 2013 Dec 13;13:599
pubmed: 24330663
Strahlenther Onkol. 2014 Jul;190(7):636-8, 640-5
pubmed: 24658605
J Natl Cancer Inst. 2016 Dec 31;109(5):
pubmed: 28040692
Cancer Res. 2000 Mar 15;60(6):1541-5
pubmed: 10749120
Eur Urol Oncol. 2019 Sep;2(5):475-482
pubmed: 31411988
Eur J Cancer. 2013 Jun;49(9):2116-25
pubmed: 23481512
Appl Immunohistochem Mol Morphol. 2019 Aug;27(7):529-534
pubmed: 29734245
In Vivo. 2019 Jul-Aug;33(4):1307-1311
pubmed: 31280223
JAMA Oncol. 2017 Sep 1;3(9):1197-1203
pubmed: 28241187
N Engl J Med. 2008 Oct 23;359(17):1757-65
pubmed: 18946061
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Anticancer Res. 2013 Apr;33(4):1257-66
pubmed: 23564763
Oncotarget. 2018 Nov 2;9(86):35623-35638
pubmed: 30479693
Science. 1997 Jul 18;277(5324):333-8
pubmed: 9219684
Nat Med. 1998 Jul;4(7):844-7
pubmed: 9662379
Ann Diagn Pathol. 2015 Oct;19(5):330-4
pubmed: 26245996
Anticancer Res. 2019 Dec;39(12):6431-6441
pubmed: 31810907
Blood. 1997 Nov 1;90(9):3322-31
pubmed: 9345014
Cancers (Basel). 2018 Apr 01;10(4):
pubmed: 29614789
J Clin Pathol. 1995 Sep;48(9):876-8
pubmed: 7490328
Clin Cancer Res. 2005 Apr 1;11(7):2518-25
pubmed: 15814628
Nature. 2014 Sep 11;513(7517):202-9
pubmed: 25079317
Anticancer Res. 2017 Mar;37(3):1349-1357
pubmed: 28314302
J Clin Oncol. 2012 Jan 20;30(3):268-73
pubmed: 22184384
Cell. 2007 Jan 12;128(1):157-70
pubmed: 17218262
Cancer. 2000 Feb 15;88(4):921-32
pubmed: 10679663
Pathophysiology. 2017 Jun;24(2):99-106
pubmed: 28262306
Pol J Pathol. 2014 Jun;65(2):135-40
pubmed: 25119174
JAMA Oncol. 2016 May 1;2(5):643-653
pubmed: 26768652
Ann Oncol. 2019 Jan 1;30(1):44-56
pubmed: 30395155
N Engl J Med. 2001 Sep 6;345(10):725-30
pubmed: 11547741
Arch Med Sci. 2017 Oct;13(6):1262-1268
pubmed: 29181056
Cancer Discov. 2018 Jan;8(1):49-58
pubmed: 29122777
Br J Cancer. 2004 Jan 12;90(1):206-15
pubmed: 14710231
Diagn Mol Pathol. 2013 Sep;22(3):127-37
pubmed: 23846438
Oncologist. 2019 Sep;24(9):e835-e844
pubmed: 30894409
Genes Cancer. 2016 Jan;7(1-2):27-35
pubmed: 27014419
Oncotarget. 2016 May 31;7(22):32731-53
pubmed: 27129168
Cancer Res. 2005 Sep 15;65(18):8096-100
pubmed: 16166282
Appl Immunohistochem Mol Morphol. 2002 Mar;10(1):1-6
pubmed: 11893029
Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1749-53
pubmed: 10677529
Cancer Biomark. 2018 Feb 14;21(3):731-741
pubmed: 29278885
Mol Biol Cell. 2006 Sep;17(9):4002-13
pubmed: 16807353
Lancet. 2012 Jan 28;379(9813):315-21
pubmed: 22226517
In Vivo. 2018 Nov-Dec;32(6):1491-1498
pubmed: 30348707
Cancer Genomics Proteomics. 2019 May-Jun;16(3):195-206
pubmed: 31018950
Ann Surg Oncol. 2016 Oct;23(11):3684-3692
pubmed: 27221363

Auteurs

Eirini Pectasides (E)

Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, U.S.A. eirini_pectasides@dfci.harvard.edu hecogoff@otenet.gr.

Ioannis Chatzidakis (I)

Second Department of Internal Medicine, Propaedeutic, Oncology Section, National and Kapodistrian University of Athens, University General Hospital Attikon, Athens, Greece.

Vassiliki Kotoula (V)

Department of Pathology, Aristotle University of Thessaloniki, School of Health Sciences, Faculty of Medicine, Thessaloniki, Greece.
Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece.

Georgia-Angeliki Koliou (GA)

Section of Biostatistics, Hellenic Cooperative Oncology Group, Athens, Greece.

Kyriaki Papadopoulou (K)

Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece.

Eleni Giannoulatou (E)

Bioinformatics and Systems Medicine Laboratory, Victor Chang Cardiac Research Institute, Darlinghurst, NSW, Australia.
The University of New South Wales, Kensington, NSW, Australia.

Vasilios G Giannouzakos (VG)

Department of Radiation Therapy, Papageorgiou Hospital, Aristotle University of Thessaloniki, School of Health Sciences, Faculty of Medicine, Thessaloniki, Greece.

Mattheos Bobos (M)

Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece.

Christos Papavasileiou (C)

Surgical Department, Papageorgiou Hospital, Aristotle University of Thessaloniki, School of Health Sciences, Faculty of Medicine, Thessaloniki, Greece.

Sofia Chrisafi (S)

Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece.

Aikaterini Florou (A)

Second Department of Internal Medicine, Propaedeutic, Oncology Section, National and Kapodistrian University of Athens, University General Hospital Attikon, Athens, Greece.

Dimitrios Pectasides (D)

Second Department of Internal Medicine, Propaedeutic, Oncology Section, National and Kapodistrian University of Athens, University General Hospital Attikon, Athens, Greece.

George Fountzilas (G)

Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece.
Aristotle University of Thessaloniki, Thessaloniki, Greece.
German Oncology Center, Limassol, Cyprus.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs épithéliales épidermoïdes et glandulaires › Carcinomes › Adénocarcinome › Prognostic Biomarkers in Early-stage Gastric...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Prognostic Biomarkers in Early-stage Gastric...
questionsmedicales.fr › Thérapeutique › Radiothérapie › Chimioradiothérapie › Chimioradiothérapie adjuvante › Prognostic Biomarkers in Early-stage Gastric...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études de suivi › Prognostic Biomarkers in Early-stage Gastric...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Prognostic Biomarkers in Early-stage Gastric...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Prognostic Biomarkers in Early-stage Gastric...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Prognostic Biomarkers in Early-stage Gastric...
questionsmedicales.fr › Diagnostic › Pronostic › Stadification tumorale › Prognostic Biomarkers in Early-stage Gastric...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines suppresseurs de tumeurs › Phosphohydrolase PTEN › Prognostic Biomarkers in Early-stage Gastric...
questionsmedicales.fr › Diagnostic › Pronostic › Prognostic Biomarkers in Early-stage Gastric...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines oncogènes › Protéines proto-oncogènes › Protéines proto-oncogènes p21(ras) › Prognostic Biomarkers in Early-stage Gastric...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Prognostic Biomarkers in Early-stage Gastric...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies gastro-intestinales › Maladies de l'estomac › Tumeurs de l'estomac › Prognostic Biomarkers in Early-stage Gastric...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Mortalité › Taux de survie › Prognostic Biomarkers in Early-stage Gastric...